-
Mashup Score: 1Emre Yekedüz: Long-term follow-up of TIVO-3 highlights key findings in CPI-treated mRCC - OncoDaily - 9 hour(s) ago
Emre Yekedüz: Long-term follow-up of TIVO-3 highlights key findings in CPI-treated mRCC / cancer, CPI-treated mRCC, Emre Yekedüz, fight against cancer, Global
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Exploring the status of online social support for older adults with cancer: A scoping review - 11 day(s) ago
The number of new cancer cases among older adults is rising, yet their social support needs remain unmet due to diminishing social networks with age. Since the COVID-19 pandemic, online technologies have provided increased opportunities for social support for this demographic via digital platforms such as online peer support groups, online communities, and chat rooms. This scoping review explores the current state of the use of online social support for older adults with cancer.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet-
RT @JGeriOnc: Exploring the status of online social support for older adults with cancer: A scoping review https://t.co/xM5NrEcQGJ @SPiller…
-
-
Mashup Score: 29Unveiling disparities in cancer care: a comparative study... : Journal of Psychosocial Oncology Research and Practice - 20 day(s) ago
ty is often set by health care professionals’ (HCPs’) evaluation about the adequacy of services and programs to meet their patients’ needs. Thus, this study aimed to compare the perspectives of HCPs from LMICs versus HICs on the availability of supportive care services for patients with cancer and survivors (Aim 1). In addition, the study examined differences in service provision across four major age groups (Aim 2) and identified the types of services offered (Aim 3). Methods: Secondary analysis was conducted using the International Psycho-Oncology Society (IPOS) Survivorship Online Survey, targeting HCPs involved in clinical services and research with patients with cancer and survivors worldwide. The data from 177 (81 from LMICs and 96 from HICs) participants were subjected to subsequent analysis. Chi-squared tests were used to compare the availability of services for each of the 13 types of unmet needs overall and across four age groups and the types of services provided between LMI
Source: journals.lww.comCategories: General Medicine News, Hem/OncsTweet-
Disparities in #SuppCare services for pts w cancer btw LMICs & HICs in addressing unmet needs like sexuality, intimacy & financial concerns Urgent policy action needed to bridge the gap #AshleyWang @csabadegi @ozanbahcivan #YoungmeeKim @IPOSPsychoOncol https://t.co/CVTVJKdKrC https://t.co/4RFncYAlDG
-
-
Mashup Score: 5A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy - PubMed - 22 day(s) ago
The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti-programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses to anti-PD-1 therapy by mod …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
RT @PavlosMsaouel: 2/5 The immunogenicity of #sitravatinib (previously noted https://t.co/tObD1sogaR) resulted in potent responses but also…
-
-
Mashup Score: 5A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy - PubMed - 22 day(s) ago
The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti-programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses to anti-PD-1 therapy by mod …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
RT @PavlosMsaouel: 2/5 The immunogenicity of #sitravatinib (previously noted https://t.co/tObD1sogaR) resulted in potent responses but also…
-
-
Mashup Score: 4Addressing educational gaps in geriatric oncology: Insights from medical oncologists - 25 day(s) ago
Most patients with cancer are 65 years or older and account for 65 % of newly diagnosed cases in Canada [1]. Older adults with cancer are more likely to experience frailty and other geriatric syndromes such as falls, cognitive impairment, and depression [2]. This population also experiences more side effects from anti-cancer therapies leading to early treatment discontinuation and reduced quality of life [3]. Specialized care focused on identifying and addressing age-associated factors is required to improve outcomes for older adults with cancer.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet-
RT @JGeriOnc: Addressing educational gaps in geriatric oncology: Insights from medical oncologists https://t.co/QnjTZ0PcHm @WilliamDale_MD…
-
-
Mashup Score: 56Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study - 25 day(s) ago
AbstractBackground. Patients with metastatic renal cell carcinoma (mRCC) experience emotional distress and limited supportive care access. This study asses
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet-
Mindfulness via smartphone @AmDTx_official Mentored by @montypal & @Linda_E_Carlson, this multinational study demonstrates that a mindfulness app improves emotional symptoms, fatigue, & QOL in patients w mRCC on IO ‼️Accessible, feasible, & impactful! https://t.co/jv4BSqGVdR https://t.co/c6D2pey1yv
-
-
Mashup Score: 3A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy - PubMed - 1 month(s) ago
The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti-programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses to anti-PD-1 therapy by mod …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
RT @PavlosMsaouel: 2/5 The immunogenicity of #sitravatinib (previously noted https://t.co/tObD1sogaR) resulted in potent responses but also…
-
-
Mashup Score: 3A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy - PubMed - 1 month(s) ago
The accumulation of immune-suppressive myeloid cells is a critical determinant of resistance to anti-programmed death-1 (PD-1) therapy in advanced clear cell renal cell carcinoma (ccRCC). In preclinical models, the tyrosine kinase inhibitor sitravatinib enhanced responses to anti-PD-1 therapy by mod …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
RT @PavlosMsaouel: 2/5 The immunogenicity of #sitravatinib (previously noted https://t.co/tObD1sogaR) resulted in potent responses but also…
-
-
Mashup Score: 2IPSON | The Irish Psychosocial Oncology Network - 1 month(s) ago
IPSON is the representative group for healthcare professionals working in the area of Psychosocial care for cancer patients.
Source: www.ipson.ieCategories: General Medicine News, Hem/OncsTweet-
RT @IRLpson: Abstract submissions for #IpsonConf2025. Our website https://t.co/kwHEybWGMu is temporarily unavailable. Conference queries t…
-
RT @DrTHut: Advancing care for patients with MRCC. https://t.co/Cm2zxEgnVM March is Kidney Cancer Month. #UMC #TTUHSC #destinationcancerce…